These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 25962435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA, Shah ZA, Pandith AA, Khan MS, Rasool R, Rasool J, Aziz SA.
    Asian Pac J Cancer Prev; 2018 Jun 25; 19(6):1479-1485. PubMed ID: 29936718
    [Abstract] [Full Text] [Related]

  • 5. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Xue M, Wang Q, Huo L, Wen L, Yang X, Wu Q, Pan J, Cen J, Ruan C, Wu D, Chen S.
    Leuk Lymphoma; 2019 Dec 25; 60(12):3051-3057. PubMed ID: 31258010
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
    Tantiworawit A, Kongjarern S, Rattarittamrong E, Lekawanvijit S, Bumroongkit K, Boonma N, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Norasetthada L.
    Asian Pac J Cancer Prev; 2016 Dec 25; 17(4):2159-64. PubMed ID: 27221912
    [Abstract] [Full Text] [Related]

  • 7. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.
    Haematologica; 2009 Oct 25; 94(10):1362-7. PubMed ID: 19713230
    [Abstract] [Full Text] [Related]

  • 8. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
    Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, de Paula EV, Lorand-Metze I, de Souza CA.
    Clin Lymphoma Myeloma Leuk; 2017 Nov 25; 17(11):728-733. PubMed ID: 28822797
    [Abstract] [Full Text] [Related]

  • 9. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, Delia M, Cumbo C, Orsini P, Specchia G, Albano F.
    Virchows Arch; 2015 Sep 25; 467(3):357-63. PubMed ID: 26149409
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
    Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J.
    Blood; 2009 Sep 10; 114(11):2232-5. PubMed ID: 19531657
    [Abstract] [Full Text] [Related]

  • 11. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 12. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL.
    Cancer Med; 2015 Jul 15; 4(7):995-1002. PubMed ID: 25756742
    [Abstract] [Full Text] [Related]

  • 13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 15; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 14. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
    Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N.
    Oncotarget; 2017 May 02; 8(18):29906-29913. PubMed ID: 28404889
    [Abstract] [Full Text] [Related]

  • 15. Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: the threats and challenges in monitoring minimal residual disease (MRD).
    Vaniawala S, Acharya A, Parekh H, Mukhopadhyaya PN.
    Anal Cell Pathol (Amst); 2013 May 02; 36(3-4):85-92. PubMed ID: 24072036
    [Abstract] [Full Text] [Related]

  • 16. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

  • 17. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ.
    Leuk Lymphoma; 2005 Sep 15; 46(9):1375-7. PubMed ID: 16109618
    [Abstract] [Full Text] [Related]

  • 18. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
    Ohm L, Arvidsson I, Barbany G, Hast R, Stenke L.
    Am J Hematol; 2012 Aug 15; 87(8):760-5. PubMed ID: 22641468
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep 15; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 20. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN, Beppu L, Radich JP.
    Biol Blood Marrow Transplant; 2015 Jan 15; 21(1):184-9. PubMed ID: 25300870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.